- Home
- FOF vs PRTA Comparison
FOF vs PRTA Comparison
Compare FOF & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- PRTA
- Stock Information
- Founded
- FOF 2006
- PRTA 2012
- Country
- FOF United States
- PRTA Ireland
- Employees
- FOF N/A
- PRTA N/A
- Industry
- FOF Investment Managers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- PRTA Health Care
- Exchange
- FOF Nasdaq
- PRTA Nasdaq
- Market Cap
- FOF 354.8M
- PRTA 472.1M
- IPO Year
- FOF N/A
- PRTA N/A
- Fundamental
- Price
- FOF $13.04
- PRTA $8.20
- Analyst Decision
- FOF
- PRTA Buy
- Analyst Count
- FOF 0
- PRTA 10
- Target Price
- FOF N/A
- PRTA $14.86
- AVG Volume (30 Days)
- FOF 58.7K
- PRTA 1.2M
- Earning Date
- FOF 01-01-0001
- PRTA 08-04-2025
- Dividend Yield
- FOF 9.07%
- PRTA N/A
- EPS Growth
- FOF N/A
- PRTA N/A
- EPS
- FOF N/A
- PRTA N/A
- Revenue
- FOF N/A
- PRTA $10,341,000.00
- Revenue This Year
- FOF N/A
- PRTA N/A
- Revenue Next Year
- FOF N/A
- PRTA $389.77
- P/E Ratio
- FOF N/A
- PRTA N/A
- Revenue Growth
- FOF N/A
- PRTA N/A
- 52 Week Low
- FOF $9.59
- PRTA $4.32
- 52 Week High
- FOF $11.75
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- FOF 58.11
- PRTA 58.73
- Support Level
- FOF $13.01
- PRTA $8.05
- Resistance Level
- FOF $13.13
- PRTA $8.73
- Average True Range (ATR)
- FOF 0.09
- PRTA 0.38
- MACD
- FOF -0.01
- PRTA -0.05
- Stochastic Oscillator
- FOF 59.05
- PRTA 47.62
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.